Literature DB >> 23250453

[Gestational diabetes mellitus].

Alexandra Kautzky-Willer1, Dagmar Bancher-Todesca, Arnold Pollak, Andreas Repa, Monika Lechleitner, Raimund Weitgasser.   

Abstract

Gestational diabetes (GDM) is defined as any degree of glucose intolerance with onset during pregnancy and is associated with increased feto-maternal morbidity as well as long-term complications in mothers and offspring. Women detected to have diabetes early in pregnancy receive the diagnosis of overt, non-gestational, diabetes. GDM is diagnosed by an oral glucose tolerance test (OGTT) or fasting glucose concentrations (> 92 mg/dl). Screening for undiagnosed type 2 diabetes at the first prenatal visit (Evidence level B) is recommended in women at increased risk using standard diagnostic criteria (high risk: history of GDM or pre-diabetes (impaired fasting glucose or impaired glucose tolerance); malformation, stillbirth, successive abortions or birthweight > 4,500 g in previous pregnancies; obesity, metabolic syndrome, age > 45 years, vascular disease; clinical symptoms of diabetes (e.g. glucosuria). Performance of the OGTT (120 min; 75 g glucose) may already be indicated in the first trimester in some women but is mandatory between 24 and 28 gestational weeks in all pregnant women with previous non-pathological glucose metabolism (Evidence level B). Based on the results of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study GDM is defined, if fasting venous plasma glucose exceeds 92 mg/dl or 1 h 180 mg/dl or 2 h 153 mg/dl after glucose loading (OGTT; international consensus criteria). In case of one pathological value a strict metabolic control is mandatory. All women should receive nutritional counseling and be instructed in blood glucose self-monitoring. If blood glucose levels cannot be maintained in the normal range (fasting < 95 mg/dl and 1 h after meals < 140 mg/dl) insulin therapy should be initiated. Maternal and fetal monitoring is required in order to minimize maternal and fetal/neonatal morbidity and perinatal mortality. After delivery all women with GDM have to be reevaluated as to their glucose tolerance by a 75 g OGTT (WHO criteria) 6-12 weeks postpartum and every 2 years in case of normal glucose tolerance (Evidence level B). All women have to be instructed about their (sevenfold increased relative) risk of type 2 diabetes at follow-up and possibilities for diabetes prevention, in particular weight management and maintenance/increase of physical activity. Monitoring of the development of the offspring and recommendation of healthy lifestyle of the children and family is recommended.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250453     DOI: 10.1007/s00508-012-0265-3

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  19 in total

Review 1.  Managing diabetes during pregnancy with insulin lispro: a safe alternative to human insulin.

Authors:  Emily J Edson; Oswaldo L Bracco; Anne Vambergue; Veikko Koivisto
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

2.  Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.

Authors:  Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson
Journal:  N Engl J Med       Date:  2005-06-12       Impact factor: 91.245

3.  Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus.

Authors:  Anny H Xiang; Miwa Kawakubo; Siri L Kjos; Thomas A Buchanan
Journal:  Diabetes Care       Date:  2006-03       Impact factor: 19.112

4.  Early possible risk factors for overt diabetes after gestational diabetes mellitus.

Authors:  Christian S Göbl; Latife Bozkurt; Thomas Prikoszovich; Christine Winzer; Giovanni Pacini; Alexandra Kautzky-Willer
Journal:  Obstet Gynecol       Date:  2011-07       Impact factor: 7.661

5.  The impact of risk factors and more stringent diagnostic criteria of gestational diabetes on outcomes in central European women.

Authors:  A Kautzky-Willer; D Bancher-Todesca; R Weitgasser; T Prikoszovich; H Steiner; N Shnawa; G Schernthaner; R Birnbacher; B Schneider; Ch Marth; M Roden; M Lechleitner
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

6.  Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.

Authors:  Robert E Ratner; Costas A Christophi; Boyd E Metzger; Dana Dabelea; Peter H Bennett; Xavier Pi-Sunyer; Sarah Fowler; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

7.  A two-step screening algorithm including fasting plasma glucose measurement and a risk estimation model is an accurate strategy for detecting gestational diabetes mellitus.

Authors:  C S Göbl; L Bozkurt; P Rivic; G Schernthaner; R Weitgasser; G Pacini; M Mittlböck; D Bancher-Todesca; M Lechleitner; A Kautzky-Willer
Journal:  Diabetologia       Date:  2012-09-22       Impact factor: 10.122

8.  Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects.

Authors:  Moshe Hod; Peter Damm; Risto Kaaja; Gerard H A Visser; Fidelma Dunne; Irina Demidova; Anne-Sofie Pade Hansen; Henriette Mersebach
Journal:  Am J Obstet Gynecol       Date:  2007-10-01       Impact factor: 8.661

Review 9.  Gestational diabetes: the need for a common ground.

Authors:  E Albert Reece; Gustavo Leguizamón; Arnon Wiznitzer
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

10.  Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis.

Authors:  Leanne Bellamy; Juan-Pablo Casas; Aroon D Hingorani; David Williams
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

View more
  7 in total

1.  Post-transcriptional down regulation of ICAM-1 in feto-placental endothelium in GDM.

Authors:  Francisca Isidora Díaz-Pérez; Ursula Hiden; Martin Gauster; Ingrid Lang; Viktoria Konya; Akos Heinemann; Jelena Lögl; Richard Saffery; Gernot Desoye; Silvija Cvitic
Journal:  Cell Adh Migr       Date:  2016-01-13       Impact factor: 3.405

2.  Pathophysiological characteristics and effects of obesity in women with early and late manifestation of gestational diabetes diagnosed by the International Association of Diabetes and Pregnancy Study Groups criteria.

Authors:  Latife Bozkurt; Christian S Göbl; Lisa Pfligl; Karoline Leitner; Dagmar Bancher-Todesca; Anton Luger; Sabina Baumgartner-Parzer; Giovanni Pacini; Alexandra Kautzky-Willer
Journal:  J Clin Endocrinol Metab       Date:  2015-01-09       Impact factor: 5.958

3.  Screening for Gestational Diabetes Mellitus: Are Guidelines From High-Income Settings Applicable to Poorer Countries?

Authors:  Bettina Utz; Patrick Kolsteren; Vincent De Brouwere
Journal:  Clin Diabetes       Date:  2015-07

4.  Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre cohort trial.

Authors:  E A Huhn; T Fischer; C S Göbl; M Todesco Bernasconi; M Kreft; M Kunze; A Schoetzau; E Dölzlmüller; W Eppel; P Husslein; N Ochsenbein-Koelble; R Zimmermann; E Bäz; H Prömpeler; E Bruder; S Hahn; I Hoesli
Journal:  BMJ Open       Date:  2016-10-12       Impact factor: 2.692

5.  Comparison of umbilical artery Doppler and non-stress test in assessment of fetal well-being in gestational diabetes mellitus: A prospective cohort study.

Authors:  Shirin Niromanesh; Mahboobeh Shirazi; Mitra Eftekhariyazdi; Forough Mortazavi
Journal:  Electron Physician       Date:  2017-12-25

6.  The participation rate of migrant women in gestational diabetes screening in Austria: a retrospective analysis of 3293 births.

Authors:  Christoph Weiss; Peter Oppelt; Richard Bernhard Mayer
Journal:  Arch Gynecol Obstet       Date:  2018-11-21       Impact factor: 2.344

7.  Exercise-Diet Therapy Combined with Insulin Aspart Injection for the Treatment of Gestational Diabetes Mellitus: A Study on Clinical Effect and Its Impact.

Authors:  Amei Mu; Yan'e Chen; Yongmei Lv; Wenxing Wang
Journal:  Comput Math Methods Med       Date:  2022-07-28       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.